Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells - Inhibitory effect of gliclazide

被引:57
作者
Mamputu, JC
Renier, G
机构
[1] Notre Dame Hosp, CHUM, Res Ctr, Montreal, PQ H2L 4M1, Canada
[2] Univ Montreal, Dept Nutr, Montreal, PQ H3C 3J7, Canada
关键词
AGEs; BRECs; VEGF; gliclazide; diabetic retinopathy;
D O I
10.1016/S1056-8727(01)00229-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Accumulating evidence points to a causal role for advanced glycation end products (AGEs) in the development of diabetic vascular complications, including retinopathy. Possible pathogenic mechanisms linking AGEs to diabetic retinopathy include protein kinase C (PKC) activation, oxidative stress, and vascular endothelial growth factor (VEGF) expression. In the present study, we investigated the effect of AGEs on VEGF expression in bovine retinal endothelial cells (BRECs) and determined the role of PKC and oxidative stress in this effect. Incubation of BRECs with AGEs led to enhanced VEGF mRNA and protein expression. This treatment also induced PKC translocation in these cells. The AGE-induced increases in VEGF expression and PKC activation were inhibited by the pan-specific PKC inhibitor, calphostin C, and by the antioxidant drug and compounds, gliclazide, N-acetylcysteine, and vitamin E. In contrast, glyburide which does not exhibit antioxidant properties, did not affect the AGE-induced VEGF expression. Exposure of BRECs to AGEs resulted in a significant increase of nuclear protein binding to the NF-kappaB consensus sequence of the VEGF promoter region. Induction of DNA binding activity for NF-kappaB by AGEs was prevented by gliclazide. Treatment of BRECs with AGEs also increased the proliferation of these cells. This effect was abrogated by incubating the cells with an anti-VEGF antibody and was inhibited in the presence of gliclazide. Overall, these data demonstrate that AGEs increase VEGF expression in retinal endothelial cells through generation of oxidative stress and downstream activation of the PKC pathway. Targeting VEGF expression with specific pharmacological agents, such as antioxidants and PKC inhibitors, may prove efficacious for the treatment of diabetic retinopathy. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:284 / 293
页数:10
相关论文
共 61 条
[1]   INCREASED VASCULAR ENDOTHELIAL GROWTH-FACTOR LEVELS IN THE VITREOUS OF EYES WITH PROLIFERATIVE DIABETIC-RETINOPATHY [J].
ADAMIS, AP ;
MILLER, JW ;
BERNAL, MT ;
DAMICO, DJ ;
FOLKMAN, J ;
YEO, TK ;
YEO, KT .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 118 (04) :445-450
[2]   Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate [J].
Adamis, AP ;
Shima, DT ;
Tolentino, MJ ;
Gragoudas, ES ;
Ferrara, N ;
Folkman, J ;
DAmore, PA ;
Miller, JW .
ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (01) :66-71
[3]   Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor [J].
Aiello, LP ;
Bursell, SE ;
Clermont, A ;
Duh, E ;
Ishii, H ;
Takagi, C ;
Mori, F ;
Ciulla, TA ;
Ways, K ;
Jirousek, M ;
Smith, LEH ;
King, GL .
DIABETES, 1997, 46 (09) :1473-1480
[4]   HYPOXIC REGULATION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR IN RETINAL CELLS [J].
AIELLO, LP ;
NORTHRUP, JM ;
KEYT, BA ;
TAKAGI, H ;
IWAMOTO, MA .
ARCHIVES OF OPHTHALMOLOGY, 1995, 113 (12) :1538-1544
[5]   SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[6]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[7]   LONG-TERM COMPARISON OF ORAL HYPOGLYCEMIC AGENTS IN DIABETIC-RETINOPATHY - GLICLAZIDE VS OTHER SULFONYLUREAS [J].
AKANUMA, Y ;
KOSAKA, K ;
KANAZAWA, Y ;
KASUGA, M ;
FUKUDA, M ;
AOKI, S .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1988, 5 (02) :81-90
[8]  
Amin RH, 1997, INVEST OPHTH VIS SCI, V38, P36
[9]  
Amirkhosravi A, 1998, THROMB HAEMOSTASIS, V80, P598
[10]   LIPID-PEROXIDATION AND RETINOPATHY IN STREPTOZOTOCIN-INDUCED DIABETES [J].
ARMSTRONG, D ;
ALAWADI, F .
FREE RADICAL BIOLOGY AND MEDICINE, 1991, 11 (04) :433-436